BASF and CTIBiotech have come to collaboration and have announced the development of the first 3D bioprinted skin models with immune macrophages. The model will be the basis for the development and testing of bio-actives for skin care applications.
The scientists at CTIBiotech will use 3D bioprinting technology of CTIBiotech to increase their 3D bioprinted skin model portfolio. The technology will be a great base for the researchers who wish to study the function of macrophages in fully reconstructed skin.
“Compared to current in vitro methods, the 3D immune bioprinted skin developed with CTIBiotech will allow analysis more in line with human physiology and the immune role of macrophages,” said Dr. Sebastien Cadau, 3D tissue engineering specialist at BASF site in Lyon, France. “That’s how technology is going to help us accelerate the development of innovative and highly reliable ingredients for the skincare market. Our understanding of an immunocompetent 3D skin provides the basis for developing and testing advanced cosmetic bio-actives for skincare applications.”
Both the research partners BASF and CTIBiotech started their collaboration in 2011 and started working on 3D tissue models for development and testing of bio-actives for skin care applications in 2015. They announced results finally in 2018 when the experts demonstrated both the ex vivo production of physiological sebum in the long-term culture of a 3D human sebaceous gland model and the regulation of this sebum production by means of active ingredients.
“CTIBiotech and BASF have a long history of collaborations on innovative human skin models to advance human skin care,” said Professor Collin McGUCKIN, Chief Scientific Officer at CTIBiotech. “CTIBiotech hosts a team of world experts for human tissue engineering with 3D Bioprinting technology that will strengthen the success of this partnership also in the future.”